

Alessandro Perez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7510236/publications.pdf>

Version: 2024-02-01

14
papers

347
citations

933264

10
h-index

1058333

14
g-index

14
all docs

14
docs citations

14
times ranked

675
citing authors

#	ARTICLE	IF	CITATIONS
1	Triple negative breast cancer: shedding light onto the role of pi3k/akt/mTOR pathway. <i>Oncotarget</i> , 2016, 7, 60712-60722.	0.8	103
2	Stabilizing versus Destabilizing the Microtubules: A Double-Edge Sword for an Effective Cancer Treatment Option?. <i>Analytical Cellular Pathology</i> , 2015, 2015, 1-19.	0.7	80
3	Dietary restriction: could it be considered as speed bump on tumor progression road?. <i>Tumor Biology</i> , 2016, 37, 7109-7118.	0.8	24
4	EGFR inhibition in NSCLC: New findings and opened questions?. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 112, 126-135.	2.0	22
5	Spheroids from adipose-derived stem cells exhibit an miRNA profile of highly undifferentiated cells. <i>Journal of Cellular Physiology</i> , 2018, 233, 8778-8789.	2.0	20
6	Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors?. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 170, 103597.	2.0	19
7	A headlight on liquid biopsies: a challenging tool for breast cancer management. <i>Tumor Biology</i> , 2016, 37, 4263-4273.	0.8	18
8	Cardiovascular Risk in Polycythemia Vera: Thrombotic Risk and Survival: Can Cytoreductive Therapy Be Useful in Patients with Low-Risk Polycythemia Vera with Cardiovascular Risk Factors?. <i>Oncology Research and Treatment</i> , 2020, 43, 526-530.	0.8	16
9	CARDIOVASCULAR RISK IN ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA: THROMBOTIC RISK AND SURVIVAL. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2020, 12, e2020008.	0.5	14
10	Management of Ponatinib in Patients with Chronic Myeloid Leukemia with Cardiovascular Risk Factors. <i>Chemotherapy</i> , 2019, 64, 205-209.	0.8	10
11	Is there any room for PD-1 inhibitors in combination with platinum-based chemotherapy as frontline treatment of extensive-stage small cell lung cancer? A systematic review and meta-analysis with indirect comparisons among subgroups and landmark survival analyses. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110180.	1.4	7
12	BRCA1/2 variants of unknown significance in hereditary breast and ovarian cancer (HBOC) syndrome: Looking for the hidden meaning. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 172, 103626.	2.0	6
13	The Essential Thrombocythemia, Thrombotic Risk Stratification, and Cardiovascular Risk Factors. <i>Advances in Hematology</i> , 2020, 2020, 1-5.	0.6	5
14	Not all KIT 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestinal stromal tumors (GISTs). <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110497.	1.4	3